"Toll-Like Receptor 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				A pattern recognition receptor that binds unmethylated CPG CLUSTERS. It mediates cellular responses to bacterial pathogens by distinguishing between self and bacterial DNA.
    
			
			
				
				
					
						| Descriptor ID | 
										
							D051217
						 | 			
					
					
						| MeSH Number(s) | 
						
							 D12.776.260.750 D12.776.543.750.705.910.500.900 
						 | 
					
					
						| Concept/Terms | 
						
							Toll-Like Receptor 9- Toll-Like Receptor 9
 - Toll Like Receptor 9
 - TLR9 Receptor
 - Receptor, TLR9
 - TLR9 Protein
 - CD289 Antigen
 - Antigen, CD289
 
  
						 | 
					
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 9".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 9".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Toll-Like Receptor 9" by people in this website by year, and whether "Toll-Like Receptor 9" was a major or minor topic of these publications. 
				
					
                    To see the data from this visualization as text, 
click here. 
				 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 2005 | 0 | 2 | 2 | 
| 2008 | 1 | 2 | 3 | 
| 2011 | 3 | 1 | 4 | 
| 2012 | 2 | 0 | 2 | 
| 2015 | 2 | 0 | 2 | 
| 2016 | 1 | 0 | 1 | 
| 2017 | 0 | 1 | 1 | 
| 2020 | 1 | 0 | 1 | 
| 2021 | 1 | 0 | 1 | 
| 2022 | 0 | 1 | 1 | 
| 2023 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Toll-Like Receptor 9" by people in Profiles.
						
					
								- 
								
The RNA receptor RIG-I binding synthetic oligodeoxynucleotide promotes pneumonia survival. JCI Insight. 2024 Nov 08; 9(21).
															
								 
							
								- 
								
Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nat Biomed Eng. 2024 May; 8(5):593-610.
															
								 
							
								- 
								
TLR2, TLR3, TLR4, TLR9 and TLR11 expression on effector CD4+ T-cell subsets in Leishmania donovani infection. Exp Parasitol. 2023 Dec; 255:108645.
															
								 
							
								- 
								
Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101). Clin Cancer Res. 2022 12 01; 28(23):5079-5087.
															
								 
							
								- 
								
Unique TLR9 Activation by Helicobacter pylori Depends on the cag T4SS, But Not on VirD2 Relaxases or VirD4 Coupling Proteins. Curr Microbiol. 2022 Mar 03; 79(4):121.
															
								 
							
								- 
								
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
															
								 
							
								- 
								
Innate immunity stimulation via CpG oligodeoxynucleotides ameliorates Alzheimer's disease pathology in aged squirrel monkeys. Brain. 2021 08 17; 144(7):2146-2165.
															
								 
							
								- 
								
Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9. J Med Chem. 2021 07 08; 64(13):9279-9301.
															
								 
							
								- 
								
Inducible Epithelial Resistance against Coronavirus Pneumonia in Mice. Am J Respir Cell Mol Biol. 2020 10; 63(4):540-541.
															
								 
							
								- 
								
CpG postconditioning after reperfused myocardial infarction is associated with modulated inflammation, less apoptosis, and better left ventricular function. Am J Physiol Heart Circ Physiol. 2020 11 01; 319(5):H995-H1007.